The authors investigated whether PCSK9 inhibition could represent a therapeutic strategy in calcific aortic valve stenosis (CAVS). A meta-analysis of 10 studies was performed to determine the impact of the PCSK9 R46L variant on CAVS, and the authors found that CAVS was less prevalent in carriers of this variant (odds ratio: 0.80 [95% confidence interval: 0.70 to 0.91]; p = 0.0011) compared with noncarriers. PCSK9 expression was higher in the aortic valves of patients CAVS compared with control patients. In human valve interstitials cells submitted to a pro-osteogenic medium, PCSK9 levels increased and a PCSK9 neutralizing antibody significantly reduced calcium accumulation.

Genetic and In Vitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis / N. Perrot, V. Valerio, D. Moschetta, S.M. Boekholdt, C. Dina, H.Y. Chen, E. Abner, A. Martinsson, H.D. Manikpurage, S. Rigade, R. Capoulade, E. Mass, M.-. Clavel, T. Le Tourneau, D. Messika-Zeitoun, N.J. Wareham, J.C. Engert, G. Polvani, P. Pibarot, T. Esko, J.G. Smith, P. Mathieu, G. Thanassoulis, J.-. Schott, Y. Bosse, M. Camera, S. Theriault, P. Poggio, B.J. Arsenault. - In: JACC. BASIC TO TRANSLATIONAL SCIENCE. - ISSN 2452-302X. - 5:7(2020 Jul), pp. 649-661. [10.1016/j.jacbts.2020.05.004]

Genetic and In Vitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis

D. Moschetta;G. Polvani;M. Camera;P. Poggio
;
2020

Abstract

The authors investigated whether PCSK9 inhibition could represent a therapeutic strategy in calcific aortic valve stenosis (CAVS). A meta-analysis of 10 studies was performed to determine the impact of the PCSK9 R46L variant on CAVS, and the authors found that CAVS was less prevalent in carriers of this variant (odds ratio: 0.80 [95% confidence interval: 0.70 to 0.91]; p = 0.0011) compared with noncarriers. PCSK9 expression was higher in the aortic valves of patients CAVS compared with control patients. In human valve interstitials cells submitted to a pro-osteogenic medium, PCSK9 levels increased and a PCSK9 neutralizing antibody significantly reduced calcium accumulation.
aortic valve interstitial cell; apolipoprotein B; calcific aortic valve stenosis; LDL cholesterol; lipoprotein(a); proprotein convertase subtilisin/kexin type 9
Settore BIO/14 - Farmacologia
lug-2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
Genetic and In Vitro Inhibition of PCSK9__649.full.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.89 MB
Formato Adobe PDF
1.89 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/758040
Citazioni
  • ???jsp.display-item.citation.pmc??? 25
  • Scopus 45
  • ???jsp.display-item.citation.isi??? 37
social impact